



MMIP  
KTN  
the Knowledge Transfer  
Network



# BioProcessing Conference

## 23<sup>rd</sup> November 2016

Ian McCubbin

# Sir Alexander Fleming




MMIP  
KTN  
the Knowledge Transfer Network





MMIP  
the Knowledge Transfer Network




VECTORWORLDMARCOM  
COPYRIGHT 2009  
This map is a reproduction of a map published by VectorWorldMarCom. The map is a reproduction of a map published by VectorWorldMarCom. The map is a reproduction of a map published by VectorWorldMarCom.

# Medicines Manufacturing in the UK

MMIP: Medicines Manufacturing Industry Partnership



MMIP  
KTN  
the Knowledge Transfer Network



# ATMT: Advanced Therapies Manufacturing Task Force

- Co-chair George Freeman, Jo Johnson, Ian McCubbin

- Task Force members:

Roger Connor (GSK)

Mark Bustard (KTN)

Natalie de Lima (GSK)

David Griffiths-Johnson (OLS)

Magda Papadaki (MMIP / ABPI)

James Miskin (Oxford Biomedica)

Virginia Acha (ABPI)

Ger Brophy (GE Healthcare)

Janet Downie (Roslin Cell Therapies)

Andrew Hadley (NHS BT)

Marc Jones (AZ)

Keith Mackay (Innovate UK)

Ian Rees (MHRA)

Matthew Speers (LSO)

Ruth McKernan (Innovate UK)

Nicole Mather (OLS)

Neil Baker (MMIP / Pfizer)

Keith Thompson (Cell & Gene Therapy Catapult)

Sarah Goulding (KTN)

Annette England (BIA)

Jim Faulkner (Autolus)

Stephen Ward (Cell & Gene Therapy Catapult)

Steve Bates (BIA)

Catriona Crombie (MRC)

Sharon Grimster (ReNeuron)

Sian Harding (British Society for Cell & Gene Therapy)

Michael Linden (Pfizer)

Declan Mulkeen (MRC)

Fergal O'Brien (CPI National Biologics Manufacturing Ctr)

Mike Sullivan (Innovate UK)

Ian Trenholm (NHS Blood & Transplant)

Nigel Perry (CPI National Biologics Manufacturing Ctr)



# ATMT: Recommended Actions



MMIP  
KTN  
the Knowledge Transfer Network



- Strengthen and secure an internationally competitive fiscal landscape to attract investment
  - strengthen R+D tax credits
  - retain Patent Box
  - reintroduce capital allowances for commercial manufacturing assets
  - better support SMEs on how to use these mechanisms
  
- Target and capture internationally mobile investments through a proactive and simplified process of engagement Competitive funding
  - Gov't to call out for company investment plans and run targeted programme to capture investments
  - Gov't to provide single point of entry for investing companies
  - appointment of Manufacturing Specialist in DIT
  - industry to provide ambassadors

# ATMT: Recommended Actions



MMIP  
KTN  
the Knowledge Transfer Network



- **Maintain science and innovation funding to support industry**
  - £30M competitive loan/grant funding for at least three years
  - establish competitive funding to support viral vector capability growth within two years
  - Gov't and industry continue to invest in manufacturing innovation
  - Ensure our sector can apply for the 'New Innovative Financial Products' currently in development by BEIS/Innovate UK
  
- **Set out an end-to-end talent management plan to secure the relevant skills**
  - industry to lead with support from multiple stakeholders
  - leverage existing initiatives
  - Seed Funding from Gov't of £1.5m to set up and coordinate

# ATMT: Recommended Actions



MMIP  
KTN  
the Knowledge Transfer Network



- **Swift, Predictable, Viable Route to Market**
  - a task and finish group to consider market challenge, AAR etc.,
  - investigate opportunities to launch pilots in the accelerated access pathway,
  - time-limited reimbursement funds to help initiate the market
  - establish a network of Cell and Gene Therapy Treatment Centres through a competitive process via Innovate UK influenced by industry
  
- **Develop a long-term regulatory strategy and plan for MHRA to lead in global standards**
  - recognise the challenges and importance of standardisation
  - MHRA, NIBSC and the BP lead a series of stakeholder engagement meetings with industry
  - enable and resource MHRA and NIBSC to deliver this



# ATMT: Outcome

- **Global Competitiveness:**
  - Fiscal environment
  - Help how to use it
  - Make it easy to do business with UK
- **Technology Investment:**
  - Competitive funding
    - Technology advancement £30m p.a. 3 years
    - Flexible funding to grow viral vector capability
    - Loan / grant of £30m p.a. 3 years for commercialisation.
- **End to End Talent Management:**
  - 400-600 jobs next 2 years
  - £1.5m seed funding
- **Route to Market:**
  - Defined process for uptake of these medicines in UK
- **Regulation:**
  - Enable MHRA to continue to lead Global partners



**Capture £350m investment in the UK over next 3 years**



MMIP





MMIP

 **KTN**  
the  
Knowledge Transfer  
Network

  
**abpi**  
Bringing medicines to *life*

  
**BIA**  
UK Biotechnology Association

